TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2554716

Group type: EXPERIMENTAL
Intervention: Danpro-S (0.8 g.kg‐1.d‐1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Danprotex-H 40 (0.8 g.kg‐1.d‐1)
Number of subjects: 17
Study: 489192

Group type: EXPERIMENTAL
Intervention: BM 15.100 (20 mg, single oral dose, administered 60 min prior to allergen inhalation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BM 15.000 (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-medicated controls
Number of subjects: 10
Study: 31904693

Group type: EXPERIMENTAL
Intervention: Comprehensive reminder system intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study: 29777048

Group type: EXPERIMENTAL
Intervention: Nasal clear corneal incision (CCI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Temporal clear corneal incision (CCI)
Number of subjects: 100
Study: 29641737

Group type: EXPERIMENTAL
Intervention: One time high dose 300,000 IU of ergocalciferol (VD2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26944107

Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter measurement in patients with pathology (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Optic nerve sheath diameter measurement in patients without pathology (Group II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Detection of midline shift using ONSD measurement
Number of subjects: 100
Study: 25586124

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg · kg(‐1) over 3 min
Number of subjects: 230

Group type: COMPARATOR
Intervention: No propofol (control group)
Number of subjects: 230
Study: 23724940

Group type: EXPERIMENTAL
Intervention: Applied tension with legs crossed (N=131)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Standard applied tension (N=133)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (N=140)
Number of subjects: 404
Study: 20823898

Group type: EXPERIMENTAL
Intervention: Meal B1 (dried and crushed whole berries)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meal B2 (supercritical fluid CO2-extracted oil-free berries)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Meal A (control)
Number of subjects: 10
Study: 18972900

Group type: EXPERIMENTAL
Intervention: Dexpanthenol spray (Mar plus)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 128
Study: 16634955

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine rinse alone (Regimen A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse preceded by SLS-containing slurry (Regimen B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse preceded by SLS-containing dentifrice (Regimen C)
Number of subjects: 120
Study: 12807299

Group type: EXPERIMENTAL
Intervention: Deer velvet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11109181

Group type: EXPERIMENTAL
Intervention: Domiciliary chemotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Hospital-based chemotherapy
Number of subjects: 87
Study: 8941405

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2/wk
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2/wk
Number of subjects: 26
Study: 1604414

Group type: EXPERIMENTAL
Intervention: Low dose pulse methotrexate (MTX, 5‐7.5mg/week)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Other DMARDs (bucillamine, D‐penicillamine, salazopyrin, auranofin, lobenzarit)
Number of subjects: 51
Study: 4055545

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg tid (open study)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg bd (comparative study)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg tid (comparative study)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Amoxycillin 500 mg tid (comparative study)
Number of subjects: 70
Study: 30747025

Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter combined with dinoprostone gel (0.5 mg) for 12 hours followed by oxytocin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intracervical Foley catheter alone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 28373691

Group type: EXPERIMENTAL
Intervention: Doxycycline (MMP inhibitor), dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26668010

Group type: EXPERIMENTAL
Intervention: Stress-induced cortisol responses
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Basal cortisol levels
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 120
Study: 25149295

Group type: EXPERIMENTAL
Intervention: 1-L polyethylene glycol and four tablets of bisacodyl with 90 mL of Iopamidol on the same day as CTC examination (group 1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard 'iodine-only' preparation, consisting of 180 mL of Iopamidol the day before the examination (group 2)
Number of subjects: 52
Study: 23123071

Group type: EXPERIMENTAL
Intervention: Pallidal neurostimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham neurostimulation
Number of subjects: 40
Study: 20008774

Group type: EXPERIMENTAL
Intervention: 0.5% Glycerol monolaurate (GML) gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5% Glycerol monolaurate (GML) gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0% Control gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control and GML gels
Number of subjects: 36
Study: 18957013

Group type: EXPERIMENTAL
Intervention: Intraperitoneal heparin (specifically low-molecular weight heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal heparin
Number of subjects: 0
Study: 15777683

Group type: EXPERIMENTAL
Intervention: 6007C > T polymorphism (TT vs. CC)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: 6007C > T polymorphism (CT vs. CC)
Number of subjects: 1232
Study: 12456902

Group type: EXPERIMENTAL
Intervention: Steroid (prednisolone) + amoxicillin for 14 days, then amoxicillin for 14 more days
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Steroid (prednisolone) + amoxicillin for 14 days, then placebo for amoxicillin for 14 more days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (for steroid) + amoxicillin for 14 days, then amoxicillin for 14 more days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (for steroid) + amoxicillin for 14 days, then placebo for amoxicillin for 14 more days
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Steroid + amoxicillin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo + amoxicillin
Number of subjects: 144
Study: 10651262

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg daily for 16 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7734716

Group type: EXPERIMENTAL
Intervention: NHL855 protocol consisting of vincristine, prednisolone, cyclophosphamide, doxorubicin, high-dose methotrexate (HD-MTX), mercaptopurine, cytarabine, CNS prophylaxis with intrathecal MTX and hydrocortisone.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NHL890 protocol with asparaginase and VP-16 added in the consolidation-maintenance phase for advanced-stage lymphoblastic lymphoma.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NHL890 protocol for advanced-stage lymphoblastic lymphoma.
Number of subjects: 69
Study: 2894175

Group type: EXPERIMENTAL
Intervention: Clorazepate
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (after switching from clorazepate or lorazepam)
Number of subjects: 62
Study: 31906339

Group type: EXPERIMENTAL
Intervention: ARA:DHA supplementation (2:1 ratio)
Number of subjects: 21

Group type: COMPARATOR
Intervention: MCT-S (control)
Number of subjects: 21
Study: 29880847

Group type: EXPERIMENTAL
Intervention: Twice or three times 100 mg aspirin daily dosing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Long-term persistence of superior biochemical efficacy with multiple dosing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Serum TXB2
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Preliminary phase results
Number of subjects: 300
Study: 28066978

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 188

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: RECIST
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: mRECIST
Number of subjects: 188
Study: 26111801

Group type: EXPERIMENTAL
Intervention: Long interdialytic period (LIDP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: First pre-HD period of the week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bradycardia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sinus arrest
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Second-degree atrioventricular block
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (VT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: New-onset paroxysmal atrial fibrillation
Number of subjects: 50
Study: 23317096

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with open flap debridement (OFD)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP) with open flap debridement (OFD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 72
Study: 21353483

Group type: EXPERIMENTAL
Intervention: Exposure to Herpes Simplex Virus type 1 (HSV‐1)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Exposure to Herpes Simplex Virus type 2 (HSV‐2)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Exposure to Cytomegalovirus (CMV)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Exposure to Toxoplasma gondii (T gondii)
Number of subjects: 1308
Study: 18362499

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for 2 years
Number of subjects: 64
Study: 22011460

Group type: EXPERIMENTAL
Intervention: Fish-oil capsules (1720 mg DHA and 600 mg EPA daily)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 391
Study: 16108295

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 40
Study: 12376165

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (triphasic OCs)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9669832

Group type: EXPERIMENTAL
Intervention: Rotahaler
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI with spacer
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Albuterol inhaled as a microfine powder
Number of subjects: 20
Study: 8148121

Group type: EXPERIMENTAL
Intervention: Rehearsal strategy training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attribution training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined rehearsal and attribution training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 0
Study: 3410667

Group type: EXPERIMENTAL
Intervention: AMSA alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AMSA + DTIC
Number of subjects: 70
Study: 12145664

Group type: EXPERIMENTAL
Intervention: Standard therapy with ribavirin
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pegylated therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pegylated combination therapy with high dose ribavirin
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sustained responders regardless of therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pegylated combination therapy
Number of subjects: 103
Study: 30517482

Group type: EXPERIMENTAL
Intervention: Composite bovine bone graft (Biomaterial Group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blood clot (Control Group)
Number of subjects: 40
Study: 27041837

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) + demineralized freeze dried bone graft (DFDBA) with open flap debridement (OFD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with open flap debridement (OFD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 30
Study: 24786931

Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg + MTX
Number of subjects: 592

Group type: COMPARATOR
Intervention: IV placebo + MTX
Number of subjects: 592
Study: 22246577

Group type: EXPERIMENTAL
Intervention: Women with major PVMD
Number of subjects: 157

Group type: COMPARATOR
Intervention: Women without major PVMD
Number of subjects: 157
Study: 21961365

Group type: EXPERIMENTAL
Intervention: Modified technique of cesarean-hysterectomy (hypogastric artery ligation before removal of uterus)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual technique of cesarean-hysterectomy
Number of subjects: 86
Study: 18549694

Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 446
Study: 15655049

Group type: EXPERIMENTAL
Intervention: alpha‐interferon (3 MU thrice weekly) + ribavirin (1000‐1200 mg/day) for 48 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: No treatment (current standard management)
Number of subjects: 98
Study: 12369033

Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine (0.2 mL 1%) by jet injector
Number of subjects: 50

Group type: COMPARATOR
Intervention: No anesthetic with a sham injection
Number of subjects: 50
Study: 10201102

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Time-out
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 7598778

Group type: EXPERIMENTAL
Intervention: Triangle-shaped hydrocolloid border dressing
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oval shape hydrocolloid dressing
Number of subjects: 103
Study: 1977029

Group type: EXPERIMENTAL
Intervention: High-dose Edmonston-Zagreb (EZ) measles vaccine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional Schwarz vaccine
Number of subjects: 180
Study: 263481

Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 210

Group type: COMPARATOR
Intervention: Personal letter
Number of subjects: 210

Group type: COMPARATOR
Intervention: Telephone call
Number of subjects: 210
Study: 31296289

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban
Number of subjects: 1083
Study: 28323627

Group type: EXPERIMENTAL
Intervention: CCXG injection (100 mL, intravenous drips, 3 times a day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (100 mL of 10% normal saline injection, 3 times a day)
Number of subjects: 55
Study: 26040478

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg administered intravaginally 10 and 4 hours before IUC insertion attempt.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo administered intravaginally 10 and 4 hours before IUC insertion attempt.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg administered intravaginally.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo administered intravaginally.
Number of subjects: 100
Study: 23549122

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Infiltration (ilioinguinal nerve block and wound infiltration)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22035998

Group type: EXPERIMENTAL
Intervention: Bupropion plus functional analytic psychotherapy (FAP) and acceptance and commitment therapy (ACT)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Bupropion alone
Number of subjects: 303
Study: 19796802

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination treatment (Gabapentin + Nortriptyline)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Combination treatment vs Gabapentin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Combination treatment vs Nortriptyline
Number of subjects: 56
Study: 16966563

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study: 12752353

Group type: EXPERIMENTAL
Intervention: Pellets (500 mg of mesalazine and 2 mg of 152Sm2O3)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tablets (500 mg of mesalazine and 2 mg of 152Sm2O3)
Number of subjects: 14
Study: 11078989

Group type: EXPERIMENTAL
Intervention: Oral fat load (OFLT) in obese subjects
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral fat load (OFLT) in healthy controls
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral fat load (OFLT) at 0700 h (diurnal test)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral fat load (OFLT) at 2200 h (nocturnal test)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Baseline insulin concentrations in obese subjects
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baseline insulin concentrations in healthy controls
Number of subjects: 41
Study: 8791965

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1637562

Group type: EXPERIMENTAL
Intervention: Cream preparations of triamcinolone acetonide and clobetasol propionate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ointment preparations of triamcinolone acetonide and clobetasol propionate
Number of subjects: 24
Study: 6712870

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29696061

Group type: EXPERIMENTAL
Intervention: Fennel vaginal cream (5 grams) every night for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo every night for 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fennel vaginal cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27295865

Group type: EXPERIMENTAL
Intervention: 10 mM oleic acid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 mM linoleic acid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 mM stearic acid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 20% sucrose followed by free fatty acids
Number of subjects: 11

Group type: COMPARATOR
Intervention: 20% sucrose
Number of subjects: 11
Study: 24695064

Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 14
Study: 22710397

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (34 g administered at 8 p.m. the night before the examination)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No preparation (no laxative administered)
Number of subjects: 50
Study: 20670236

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine for palatal block
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Normal saline for palatal block
Number of subjects: 45

Group type: COMPARATOR
Intervention: No block (control group)
Number of subjects: 45
Study: 17204156

Group type: EXPERIMENTAL
Intervention: Alcohol and drug abuse and dependence (AAD/DAD) assessment using standardized procedures and structured interviews.
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Cannabis use among prisoners.
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Alcohol abuse and dependence (AAD) prevalence.
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Comparison of AAD and DAD profiles.
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Regular screening and treatment programs for AAD/DAD in prison.
Number of subjects: 998
Study: 16123473

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular human insulin (RHI)
Number of subjects: 20
Study: 12215236

Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg/24 h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 16
Study: 10051966

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (6 mg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 7981578

Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing hormone (GHRH; 100 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose tolerance test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 12
Study: 2493400

Group type: EXPERIMENTAL
Intervention: Buserelin (0.2 mg SC or 1.2 mg IN per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Danazol (800 mg per day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 26
Study: 1105370

Group type: EXPERIMENTAL
Intervention: Pyritinol-HCl 300 mg/24 hr
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pyritinol-HCl
Number of subjects: 67
Study: 31642130

Group type: EXPERIMENTAL
Intervention: Intervention workbook plus device (WD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intervention workbook only (WO)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 30366723

Group type: EXPERIMENTAL
Intervention: Nebulized ropivacaine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Saline nebulization (placebo)
Number of subjects: 116
Study: 27779370

Group type: EXPERIMENTAL
Intervention: Planning strategies (implementation intentions and coping plans)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No planning (control condition)
Number of subjects: 71
Study: 26898264

Group type: EXPERIMENTAL
Intervention: Z applicator
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IR applicator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional drug therapy (Control)
Number of subjects: 30